The Fall of precision medicine: An explicit equivocation strategy, where FCH is the real target.

Dr. Seth Baum’s Exclusionary Criteria is MEDPED: 2014 vs. 1993-1996

Dr. Seth Baum was paid the most money from Aegerion for promoting its product to other doctors … and to investors. Aegerion was and still is under intense federal scrutiny, despite the $40 million-dollar settlement with various federal agencies. Now Dr. Baum receives payment from Amgen. In 2014 Dr. Baum explained an “evolution of a definition” of FH and actually proposed a “language strategy.” There is the discouragement of genetic testing, but the assault on Williams’ solution to base rate fallacy is the first point I will make about this industry-funded reversal toward imprecision medicine. Dr. Williams’ use of prior probabilities when identifying FH was known as MEDPED.  Dr Baum devalues and discourages use of the original MEDPED system.  And he does so by misrepresenting the historical record. It is easy to do because working with prior probability is so counterintuitive it remains invisible as the first step of a two-step procedure. In truth, after establishing the first step of enriching prior probability, the second step is to check LDL-C levels, and this sequence yields more efficient results. Unfortunately, the idea of overcoming base rate fallacy is now lost and replaced with the default of the fact-ectomy: the now unimpeded employment of the fallacy.

Dr. Seth Baum’s Exclusionary Criteria is MEDPED: 2014 vs. 1993-1996